Important highlight from Alere’s Q4 earnings session:

“Additionally, in January we launched our Cardiorenal panel in Europe, for use on the Triage platform. The Cardiorenal panel is the world’s first point of care test to combine BNP and NGAL to aid in the real-time assessment of cardiac and renal status. We believe this panel will continue to support greater adoption of NGAL as a novel biomarker for the evaluation of kidney function.”

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years :)

Tagged with:
 

What do you say?

Set your Twitter account name in your settings to use the TwitterBar Section.